Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug, sotorasib, to see if it is safe and effective in treating adults with KRAS p.G12C mutant advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a primary brain tumor.I have not had a heart attack in the last 6 months.I do not have active brain issues related to my cancer.My cancer is advanced or has spread, and tests show a KRAS mutation.I am 18 years old or older.I cannot take pills due to a stomach or intestine problem.
- Group 1: Sotorasib + MVASI® (bevacizumab-awwb)+ Chemotherapy
- Group 2: Sotorasib + panitumumab +/- chemotherapy
- Group 3: Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab
- Group 4: Sotorasib + trametinib + panitumumab
- Group 5: Sotorasib + afatinib
- Group 6: Sotorasib + palbociclib
- Group 7: Sotorasib + BI 1701963
- Group 8: Sotorasib + AMG 404
- Group 9: Sotorasib Monotherapy
- Group 10: Sotorasib + atezolizumab
- Group 11: Sotorasib + TNO155
- Group 12: Sotorasib + pembrolizumab
- Group 13: Sotorasib + everolimus
- Group 14: Sotorasib + RMC-4630
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the trial open to senior citizens?
"Only individuals between the ages 18 and 100 can enroll in this medical trial, while 634 studies are available to minors and 5448 trials accommodate seniors."
Are individuals still able to join this research endeavor?
"Confirmed. Records found on clinicaltrials.gov reveal that this medical research, first posted in December of 2019 is still recruiting patients nationwide. 1054 participants are expected to be enrolled across 52 locations before the study's completion date of September 1st 2022."
How many healthcare facilities are hosting this clinical investigation?
"A plethora of medical sites are available for this study, such as Texas Oncology-Tyler in Tyler, Texas Oncology-Tyler in Quebec, and CHU de Quebec Hopital de l Enfant Jesus in Fairfax. In total, 52 different locations have been identified and approved by the research team."
Who qualifies to partake in this trial?
"This medical trial is calling for 1054 people with cancer aged 18-100 years. Criteria to be met by applicants include: both male and female candidates of the legal age, a biopsy-confirmed diagnosis of advanced or metastasised malignancy, and KRAS p.G12C mutation detected via molecular testing that must abide by US regulations (i.e., conducted in CLIA certified laboratories)."
To what medical purpose is Sotorasib typically prescribed?
"Sotorasib is typically prescribed to manage melanoma, but can also assist patients with macrocytic anemia, prior systemic therapy and malignant skin melanomas."
Share this study with friends
Copy Link
Messenger